Ken Hinds

Ken Hinds is an accomplished executive in the pharmaceutical industry with extensive experience in drug product development and formulation. Currently serving as Executive Director of Dosage Form Design and Development at AstraZeneca since September 2018, Ken has previously held significant roles at The Janssen Pharmaceutical Companies of Johnson & Johnson as Scientific Director and at Johnson & Johnson in various positions, including Associate Director and Principal Research Scientist. Ken’s career in R&D began at PR Pharmaceuticals, and academic credentials include a Ph.D. in Pharmaceutics from the University of Utah.